Work

Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial

Year: 2020

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs19-p4-10-02

Authors: Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Smita M. Asare, Gillian L. Hirst, Laura Sit, Jane Perlmutter, Minetta Liu, John Park, Angela DeMichele, Douglas Yee, Don Berry, Laura Esserman, Emanuel Petricoin, Laura van t' Veer

Institutions: University of California, San Francisco, George Mason University, Quantum Leap Healthcare Collaborative, Mayo Clinic, University of Pennsylvania, University of Minnesota, Berry Consultants, LLC (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3013390284

Cites:

Cited by: 1

Related to: 10